VEA
KYMR icon

Virtus ETF Advisers’s Kymera Therapeutics KYMR Stock Holding History

Virtus ETF Advisers’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,686
Closed -$67.8K – 626
2024
Q4 		$67.8K Sell
1,686
-954
-36% -$43.1K 0.03% 400
2024
Q3 		$125K Buy
2,640
+44
+2% +$1.94K 0.06% 346
2024
Q2 		$77.5K Sell
2,596
-811
-24% -$28.1K 0.04% 418
2024
Q1 		$137K Sell
3,407
-231
-6% -$8.27K 0.07% 337
2023
Q4 		$92.6K Sell
3,638
-199
-5% -$3.56K 0.06% 396
2023
Q3 		$53.3K Sell
3,837
-378
-9% -$7.6K 0.03% 411
2023
Q2 		$96.9K Buy
4,215
+796
+23% +$22.8K 0.06% 398
2023
Q1 		$101K Sell
3,419
-1,310
-28% -$42.2K 0.06% 335
2022
Q4 		$118K Sell
4,729
-2,493
-35% -$66.5K 0.06% 422
2022
Q3 		$157K Buy
7,222
+51
+0.7% +$1.34K 0.06% 346
2022
Q2 		$141K Buy
7,171
+4,273
+147% +$99.8K 0.05% 328
2022
Q1 		$123K Sell
2,898
-173
-6% -$7.31K 0.06% 260
2021
Q4 		$195K Sell
3,071
-1,134
-27% -$66K 0.07% 216
2021
Q3 		$247K Sell
4,205
-216
-5% -$12.5K 0.11% 221
2021
Q2 		$214K Buy
+4,421
New +$192K 0.09% 294

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Virtus ETF Advisers's KYMR Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Kymera Therapeutics (KYMR) in Q1 2025, closing a stake of 1,686 shares — an estimated $67.8K sold.

Virtus ETF Advisers first reported a position in KYMR in Q2 2021 and held it in 15 quarters. The position peaked at $247K in Q3 2021. 173 funds tracked by Wall St. Rank hold KYMR as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Kymera Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,686 Kymera Therapeutics shares in Q1 2025, an estimated $67.8K.
  • Virtus ETF Advisers first reported a position in Kymera Therapeutics in Q2 2021 and held it in 15 quarters.
  • Virtus ETF Advisers's Kymera Therapeutics position peaked at $247K in Q3 2021.
  • 173 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.